D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating restated by research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $30.00 target price on the stock.

Separately, EF Hutton Acquisition Co. I upgraded ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd.

ImmunityBio Trading Down 1.9 %

IBRX traded down $0.05 during midday trading on Friday, hitting $2.62. 7,861,021 shares of the company were exchanged, compared to its average volume of 5,066,788. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -2.85 and a beta of 0.86. The company's 50 day simple moving average is $4.49 and its 200 day simple moving average is $4.74. ImmunityBio has a 1-year low of $2.61 and a 1-year high of $10.53.

Hedge Funds Weigh In On ImmunityBio

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its holdings in shares of ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company's stock valued at $3,928,000 after acquiring an additional 170,742 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after purchasing an additional 4,545 shares in the last quarter. Private Advisor Group LLC boosted its stake in ImmunityBio by 727.7% during the 2nd quarter. Private Advisor Group LLC now owns 86,907 shares of the company's stock worth $549,000 after purchasing an additional 76,407 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in shares of ImmunityBio during the second quarter worth $118,000. Finally, Rhumbline Advisers grew its holdings in shares of ImmunityBio by 13.3% during the second quarter. Rhumbline Advisers now owns 211,677 shares of the company's stock worth $1,338,000 after buying an additional 24,802 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.